Victory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Victory Capital Management Inc. grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 3.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 262,689 shares of the specialty pharmaceutical company's stock after buying an additional 9,390 shares during the period. Victory Capital Management Inc. owned 0.43% of Jazz Pharmaceuticals worth $32,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $25,000. Jones Financial Companies Lllp lifted its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 130 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after purchasing an additional 129 shares during the last quarter. Itau Unibanco Holding S.A. lifted its holdings in shares of Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock valued at $49,000 after purchasing an additional 172 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Jazz Pharmaceuticals by 49.8% in the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company's stock valued at $76,000 after purchasing an additional 206 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This represents a 10.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,193 shares of company stock worth $3,533,122. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $138.81 on Monday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The business's 50 day moving average is $128.14 and its two-hundred day moving average is $120.07. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The stock has a market capitalization of $8.43 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 1.04 and a beta of 0.44.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JAZZ. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a report on Monday, November 18th. JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, Piper Sandler restated an "overweight" rating and issued a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $189.40.

Remove Ads

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.